AI in Healthcare and Life Sciences
Applied AI in medicine, biology, drug discovery, diagnostics, clinical workflows, research labs, and healthcare administration.
AI Research Agents Are Advancing First Where Results Can Be Checked Quickly
Richard Socher, former chief scientist at Salesforce and founder of You.com and Recursive, argues that AI can move from assisting researchers to conducting parts of research—but only where systems can test ideas and verify results. Recursive is beginning with AI research on AI, where software benchmarks provide fast feedback; extending the approach to biology and other physical sciences will require more data, computing power and experimental infrastructure. Socher says rapid self-improvement is possible, but not a shortcut around those constraints.
Whole-Genome Embryo Screening Can Reveal Risks Standard IVF Tests Miss
Noor Siddiqui argues that whole-genome sequencing can give parents using IVF information about embryo health risks that standard tests leave unread. Her company, Orchid, uses the technology to help parents choose among embryos; Siddiqui says this could reduce the risk of serious inherited disease. In her talk, she also discusses traits such as endurance and bone density, while leaving open where society should draw the line between disease screening and selecting for other characteristics.
A Sustainable Care System Must Work for Families and Workers
At the WIN Summit, Olympic bobsledder Elana Meyers Taylor described the caregivers who helped make her athletic career and family life possible—and the limits of a system that many families cannot afford. Taylor argued that access to care and fair pay for care workers must be addressed together; Ai-jen Poo, executive director of Caring Across Generations, called for affordable, quality care and good jobs for the people who provide it.
AI Adoption Is Widening the Gap Between Frontier Firms and Their Peers
OpenAI CFO Sarah Friar argues that expanding access to AI and managing its risks are inseparable: the company’s mission requires it to make powerful tools available while sometimes holding back models until safety concerns are addressed. In a conversation with Reid Hoffman, she also contends that AI is changing work within jobs, with leading companies adopting agents faster than their peers. Friar says public trust will depend on demonstrated benefits—in healthcare and business, and for communities hosting data centers—rather than assurances alone.
Connected AI Tools Link Patient Reports, Clinical Plans, and Recovery Support
The article argues that connected digital systems are intended to carry a patient’s account from one setting into the next decision, while equipment and supplies support care teams where they are needed. In its consultation example, a transcription tool records the patient’s account, the clinician’s assessment and the follow-up plan; it supports the clinician’s work, rather than making the decision.
AI Models and Robotic Labs Narrow Candidates for B-Cell Lymphoma Therapy
Lila Sciences is connecting AI agents to an autonomous laboratory to search for candidate therapies intended to help a patient’s own immune cells fight B-cell lymphoma. The company’s workflow uses Iris, built on NVIDIA Nemotron and Agent Toolkit, to turn a research goal into an experimental plan; models built with NVIDIA BioNeMo then run millions of virtual experiments to narrow candidates before robots make and test them. Lab results feed back into the next round of designs, though the source presents a research process, not a finished therapy.
NVIDIA’s GTC Berlin Keynote Frames Tokens as a Path From Data to Action
NVIDIA CEO Jensen Huang’s GTC Berlin keynote opening video presents tokens as the building blocks that turn data into knowledge and action. Its examples range from treatment planning and crowd forecasts to robots carrying medical samples and inspecting hazardous sites, connecting AI to decisions and physical work. The video places those examples alongside computing infrastructure and closes with a shared ambition for a future built for all humankind.
AI Agents Link Virtual Experiments to Lab Tests, Factory Plans to Floor Conditions
NVIDIA’s GTC Berlin presentation argues that industrial AI agents need more than a model: they must connect to company knowledge and domain-specific tools, with controls over what they can access and execute. It illustrates that architecture through Lila Sciences’ experiments for therapy design, Siemens’ production planning and Dassault Systèmes’ vehicle-design workflow. Lila feeds physical test results into another round of designs and experiments; in Dassault Systèmes’ example, simulation results prompt refinement before an engineer selects the final design.
Virtual Cells Need Better Measurements Before They Can Predict Cell Behavior
Biohub Head of Science Alex Rives argues that modeling cellular biology requires more than larger AI models: researchers need measurements that reveal how cells behave in context, alongside approaches suited to biology’s complexity. He describes the $1.8 billion partnership as a flagship effort within the broader Virtual Biology Initiative to coordinate data generation, including maps of hundreds of billions of cells. An information-level model of cell states is a nearer step toward a broader world model of life; whether such models can help identify therapeutic interventions remains an open question.
Narcolepsy Went Undiagnosed for 19 Years as Exhaustion Was Mistaken for Laziness
For nearly two decades, sleep health educator Lindsay Scola treated her exhaustion as the cost of ambition, until a narcolepsy diagnosis showed that what she had taken for laziness was a neurological disorder. In her TEDx talk, she argues that many people with sleep disorders remain undiagnosed because symptoms are mistaken for ordinary tiredness and medical training gives sleep too little attention. She urges people whose fatigue feels unusual to seek answers beyond sleep-hygiene advice.
AI’s Defender’s Window Is a Chance to Repair Longstanding Security Debt
OpenAI President and co-founder Greg Brockman argues that frontier AI can accelerate scientific discovery and help defenders find and repair vulnerabilities before cyber capabilities spread more widely. He cites nearly 400 solved mathematical problems as evidence that models can produce new knowledge, while stressing that fields such as biology still face data and process bottlenecks. Across science, security and workplace agents, Brockman says, greater capability must be matched by human oversight and control.
Billy Evans Disputes Elizabeth Holmes’s Investor-Fraud Convictions
Billy Evans disputes Elizabeth Holmes’s convictions for defrauding three investors and conspiring with her former partner, but does not fully explain why he believes the verdict was wrong. He points to Holmes’s acquittal on charges of defrauding patients, arguing that four patient cases did not show a problem across the 12.5 million tests Theranos ran, according to Evans.
Big Pharma’s Overlooked Drugs Can Become Billion-Dollar Businesses
Martin Shkreli argues that a technology’s technical breakthrough does not make it a sound investment: quantum computing may excel at a narrow set of problems, he says, without offering a viable business case. In a conversation with the Besties, he also describes pharmaceutical opportunity as finding drugs large companies have failed to develop well, while disputing claims that AI will soon transform drug discovery. Looking back on prison, Shkreli says his fixation on being a great trader obscured other paths and relationships that mattered more.
Indian Mental-Health Programs Bring Treatment Into Shrines and Communities
With one psychiatrist for every 133,000 people in India, the film examines two community approaches to extending mental-health care: Dawa-Dua connects prayer at Gujarat’s Mira Datar shrine with treatment at a nearby clinic, while Parivartan trains local workers in Maharashtra to identify symptoms and connect people with care. Dawa-Dua works through a relationship families already trust without asking them to give up faith; Parivartan’s psychiatrist Hamid Dabholkar argues that community workers are essential to reaching people specialists cannot serve alone.
Oura Tests Whether Continuous Monitoring Can Improve Care
Oura Chief Medical Officer Ricky Bloomfield argues that wearable devices can fill a gap in conventional care by tracking health between brief doctor visits and flagging changes earlier. But he says continuous data matters only when it prompts clinical review or helps people change their behavior; a ring’s signal, for example, is not itself a diagnosis. Oura is testing that approach with a Medicare Advantage plan, while evaluating whether the program produces health and economic benefits.
AlphaGenome Atlas Precomputes Predictions for Nearly Every Single-Letter DNA Change
Google DeepMind’s AlphaGenome is designed to predict how individual DNA changes affect molecular processes such as gene expression and splicing, not to predict a person’s disease risk. Pushmeet Kohli, who described the model, argues that its combination of a million-base-pair context window and single-base precision can help researchers investigate variants whose effects remain poorly understood. The accompanying AlphaGenome Atlas makes predictions for roughly nine billion possible single-letter changes available for research, while linking them to whole-person outcomes remains an open task.
Neural Technology’s Promise Outpaces Our Understanding of the Brain
Neuroscientist Andrew Huberman argues that major AI labs will become biotech companies because their ambitions extend beyond language models to reading and changing brain activity. In a discussion with Patrick O’Shaughnessy, he describes non-invasive neural control as a possible frontier, but says researchers still lack a clear account of how thought and memory work—an uncertainty that limits what such technology can safely and reliably do.
Methylone’s Promise Met the High Cost of FDA Development
Kevin Ryan says he moved from funding Yale psychedelic research to building a company around methylone because developing a drug through FDA approval could cost $200 million to $250 million—too much for philanthropy alone. In a discussion with Tim Ferriss, he describes the company’s rationale and the financial limits that forced it to begin with one indication. Despite the title’s $700 million figure, the discussion does not explain a sale or provide transaction details.
Meta’s Consumer AI Strategy Puts Integration Ahead of Benchmark Leadership
John Coogan argues that Meta’s consumer-AI strategy is becoming clearer: rather than win every model benchmark, the company can pair capable agents with its infrastructure, hardware and reach. He sees Muse as a practical assistant for ordinary tasks, while Jordi Hays questions whether Meta’s devices will keep users beyond their initial appeal.
Anthropic Reports a New Enzyme System With CRISPR-Like Repeats
Anthropic’s new molecular biology group is using Claude to search large DNA datasets for proteins that scientists may not recognize or understand. The researchers say the model helps widen the pool of candidates, while they decide which ones merit experiments; in an early research program, they report finding a novel enzyme system with CRISPR-like repeats.
Erectile Dysfunction in Younger Men May Reflect Conditioning, Anxiety, and Vascular Health
Dr. Alok Kanojia argues that erectile difficulties among younger men often reflect an inability to sustain an erection during partnered sex rather than a simple failure to become erect. He attributes the pattern primarily to conditioning from habitual masturbation and pornography, cardiovascular health and anxiety—not, in most cases, to low testosterone—and proposes a short abstinence period followed by lower-pressure, lubricated masturbation without porn, alongside exercise and relaxation.
Australia Opened a Restricted Prescribing Pathway for MDMA and Psilocybin
Mind Medicine Australia co-founder Tania de Jong argues that Australia’s 2023 decision to permit tightly controlled prescribing of MDMA for PTSD and psilocybin for treatment-resistant depression was won not by a single regulatory application, but by building the clinical, political and public infrastructure around it. Her account is a procedural one: revise rejected submissions against regulators’ objections, mobilize patients and clinicians, recruit scientific allies, train a workforce before approval and prepare systems for data collection and payment. The result remains a restricted psychiatric pathway, not broad legalization—and its durability now depends on whether access can expand without compromising supervision or affordability.
Astra Signals OpenAI’s Shift From Chatbots to Computer-Using Agents
OpenAI president Greg Brockman argues that AI should move beyond chat interfaces that require users to choose models, tools and settings, toward systems that can determine how to complete a task while remaining open to human oversight. He presents Astra, OpenAI’s computer-use system, as evidence that agents can now work across software designed for people, while describing the earlier Operator release as a necessary but insufficient deployment that exposed the reliability and speed such systems require. In health, Brockman says the same model depends on earning enough trust to connect the fragmented information held by patients, clinicians and hospitals.
Insulin Testing Could Reveal Metabolic Risk Before Blood Sugar Rises
Dr Mark Hyman argues that US healthcare is built to treat diagnosed disease rather than identify the metabolic and nutritional problems that precede it. Through Function Health, Hyman is making the case for patient-held, longitudinal records that combine laboratory tests, imaging, wearables and medical history, with AI used to organize the data under clinician supervision. He says routinely overlooked measures such as insulin and ApoB can reveal risk hidden by normal blood-sugar readings, while warning that wider testing and GLP-1 use require careful interpretation, follow-up and muscle-preserving care.